Skip to content
ESPT
MARKETS / NYSE / Health care / Medical devices and instruments / A
NYSE · LABORATORY ANALYTICAL INSTRUMENTS · LARGE CAP

Agilent Technologies, Inc. A

19 fiscal years on record · USD · FY2025 reported · SEC filings only
10 YEARS OF DIVIDEND GROWTH
$6.9B
▲ 6.7% YoY
$1.3B
▲ 1.1% YoY
$1.2B
▼ 16.1% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Agilent Technologies, Inc. provides application-focused solutions, including instruments, software, services and consumables, for the entire laboratory workflow. As of October 31, 2025, it employed approximately 18,100 people, of whom approximately 7,100 were based in the Americas, 4,400 in Europe and 6,600 in Asia Pacific. Following a November 2024 reorganization, the company has three business segments, each a reportable segment: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Agilent Technologies, Inc. was incorporated in Delaware in May 1999.

Written from the business description in AGILENT TECHNOLOGIES, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 22 December 2025. Every sentence was checked against that document before publication.

Growth

USD 6.9B
Revenue, FY2025 · full 19-year series below
Revenue $B Net income $B
FY2025 · Revenue 6.9 · Net income 1.3
2.5B5.0B
2007201020132016201920222025
Compound annual growth
+0.5%
+5.4%
+5.6%
+1.6%
+1.3%
+12.6%
+3.0%
+14.7%
+14.3%
+5.9%
+5.7%
+6.6%
+9.5%
−20.2%
+0.5%
+5.9%
+3.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +5.4% a year over the five years to FY2025 — but profit grew faster: net income at +12.6%, earnings per share at +14.7%.

The share count fell from 0.31B to 0.28B — the buyback concentrates the same profit into fewer slices.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

19 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 21.3% · Net 18.8%
10%20%
200720162025
ROE
FY2025 · ROE 20.6%
10%20%
200720162025
Three returns, three denominators.
Gross margin52.4%
Operating margin21.3%
Net margin18.8%
EBITDAUSD 1.8B

Each USD of equity produced 21 cents of profit this year.

Cash & shareholders

USD 707.0M
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF 1.2
1B2B
200720162025
Net buybacks $B Dividends $B
FY2025 · Dividends 0.3 · Net buybacks 0.4
1B2BDividendsNet buybacks
2007201020132016201920222025
Dividends paidUSD 282.0M
Net buybacksUSD 425.0M
Share of profit54.3%
Consecutive raises10 years

USD 282.0M in dividends and USD 425.0M in buybacks — 54% of the year's profit went back to shareholders.

Total assetsUSD 12.7B
EquityUSD 6.7B
CashUSD 1.8B
Gross debtUSD 3.4B
Net debtUSD 1.6B
Current ratio1.96×

Net debt stands at 23% of equity.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
A, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B6.96.56.86.86.35.35.24.94.54.24.04.03.96.96.65.44.55.85.4
Operating income $B1.51.51.41.61.30.80.90.90.80.60.50.40.41.11.10.60.00.80.6
EBITDA $B1.81.71.61.91.71.21.21.11.00.90.80.80.81.41.30.80.21.00.8
Income tax $B0.10.20.10.20.10.1−0.20.60.10.10.0−0.00.1−0.10.00.00.00.10.0
Net income $B1.31.31.21.31.20.71.10.30.70.50.40.50.71.21.00.7−0.00.70.6
Free cash flow $B1.21.41.51.01.30.80.90.90.70.70.40.51.01.01.10.60.30.60.8
EPS, diluted $4.574.434.194.183.942.303.370.972.101.401.201.622.133.272.851.94−0.091.871.57
Dividend / sh $0.990.940.900.840.780.720.660.600.530.460.400.530.460.300.000.00◌◌◌
Payout %22212120203119602532333221900———
ROE %20.622.022.223.523.614.923.06.715.111.08.510.414.024.326.923.9−1.223.919.7
Shares out B0.280.290.290.300.300.310.31◌◌◌◌◌◌◌◌◌◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 74 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Two checks were skipped: the balance sheet is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityLaboratory Analytical Instruments
Listed onNYSE
Incorporated inDelaware
Fiscal year endsOctober 31
Data on record since2007

Share this section

Download image